Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Incyte < Previous 1 2 3 Next > Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress May 14, 2024 From Incyte Via Business Wire Tickers INCY Incyte to Present at Upcoming Investor Conference May 02, 2024 From Incyte Via Business Wire Tickers INCY Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs April 30, 2024 From Incyte Via Business Wire Tickers INCY Incyte to Report First Quarter Financial Results April 11, 2024 From Incyte Via Business Wire Tickers INCY Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia April 01, 2024 From Incyte Via Business Wire Tickers INCY Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) March 29, 2024 From Incyte Via Business Wire Tickers INCY Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis March 10, 2024 From Incyte Via Business Wire Tickers INCY New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting March 04, 2024 From Incyte Via Business Wire Tickers INCY Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI February 29, 2024 From Incyte Via Business Wire Tickers INCY Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease February 27, 2024 From Incyte Via Business Wire Tickers INCY Incyte to Present at Upcoming Investor Conference February 15, 2024 From Incyte Via Business Wire Tickers INCY Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities February 13, 2024 From Incyte Via Business Wire Tickers INCY Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®) February 05, 2024 From Incyte Via Business Wire Tickers INCY Incyte to Report Fourth Quarter and Year-End 2023 Financial Results January 23, 2024 From Incyte Via Business Wire Tickers INCY Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference January 08, 2024 From Incyte Via Business Wire Tickers INCY Incyte to Present at Upcoming Investor Conferences December 12, 2023 From Incyte Via Business Wire Tickers INCY Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting November 02, 2023 From Incyte Via Business Wire Tickers INCY Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs October 31, 2023 From Incyte Via Business Wire Tickers INCY Science Magazine Recognizes Incyte as #2 “Top Employer” of 2023 October 27, 2023 From Incyte Via Business Wire Tickers INCY Incyte to Present at Upcoming Investor Conferences October 18, 2023 From Incyte Via Business Wire Tickers INCY Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023 October 16, 2023 From Incyte Via Business Wire Tickers INCY Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis October 13, 2023 From Incyte Via Business Wire Tickers INCY Data From Incyte’s Povorcitinib Clinical Program to Be Featured at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA) October 13, 2023 From Incyte Via Business Wire Tickers INCY New Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura® (Ruxolitinib) Cream in Nonsegmental Vitiligo Patients October 11, 2023 From Incyte Via Business Wire Tickers INCY Incyte and Mandy Moore Partner to Empower People with Atopic Dermatitis to Find Their Moments of Clarity October 11, 2023 From Incyte Via Business Wire Tickers INCY Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo October 11, 2023 From Incyte Via Business Wire Tickers INCY Incyte to Report Third Quarter Financial Results October 10, 2023 From Incyte Via Business Wire Tickers INCY Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress September 29, 2023 From Incyte Via Business Wire Tickers INCY Incyte to Present at Upcoming Investor Conferences August 22, 2023 From Incyte Via Business Wire Tickers INCY Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma July 31, 2023 From Incyte Via Business Wire Tickers INCY REPL < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.